Added value of quantiFERON TB-gold in-tube for detecting latent tuberculosis infection among persons living with HIV/AIDS

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Souza, Josiane Maria Oliveira ^a,b   Evangelista, Maria Do Socorro Nantua ^a,c   Trajman, Anete ^d,e  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b SHA   (Brazil)

^c UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIVIRAL THERAPY; ARTICLE; BCG VACCINATION; BRAZIL; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS TEST KIT; OUTPATIENT DEPARTMENT; SEQUENTIAL ANALYSIS; SEROLOGY TEST KIT; TUBERCULIN TEST; ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPLICATION; INTERFERON GAMMA RELEASE ASSAY; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; TUBERCULIN TEST;

EID: 84902194690     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/294963     Document Type: Article

References (34)

1. World Health Organization, Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings 2011 Geneva, Switzerland World Health Organization
2. World Health Organization, Global Tuberculosis Report 2013 2013 Geneva, Switzerland World Health Organization
3. Dierberg K. L., Chaisson R. E., Human immunodeficiency virus-associated tuberculosis. Update on prevention and treatment. Clinics in Chest Medicine 2013 34 2 217 228 2-s2.0-84878137436 10.1016/j.ccm.2013.02.003
4. Samandari T., Agizew T. B., Nyirenda S., Tedla Z., Sibanda T., Shang N., Mosimaneotsile B., Motsamai O. I., Bozeman L., Davis M. K., Talbot E. A., Moeti T. L., Moffat H. J., Kilmarx P. H., Castro K. G., Wells C. D., 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. The Lancet 2011 377 9777 1588 1598 2-s2.0-79955694277 10.1016/S0140-6736(11)60204-3
5. Lawn S. D., Wood R., de Cock K. M., Kranzer K., Lewis J. J., Churchyard G. J., Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. The Lancet Infectious Diseases 2010 10 7 489 498 2-s2.0-77953648371 10.1016/S1473-3099(10)70078-5
6. National Institute for Health and Clinical Excellence, Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control 2011 London, UK National Institute for Health and Clinical Excellence
7. World Health Organization, WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and Other Stakeholder 2012 Geneva, Switzerland World Health Organization
8. Kaplan J. E., Benson C., Holmes K. H., Brooks J. T., Pau A., Masur H., Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the national institutes of health, and the HIV medicine association of the infectious diseases society of America. Morbidity and Mortality Weekly Report: Recommendations and Reports 2009 58 4 1 207 2-s2.0-64249152335
9. Ministério da Saúde (Brasil), Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais, Protocolo Clínico e Diretrizes Terapêuticas para Adultos vivendo com HIV/Aids: versão preliminar 2013 Brasília, Brazil Ministério da Saúde
10. Menzies D., Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. The American Journal of Respiratory and Critical Care Medicine 1999 159 1 15 21 2-s2.0-0032902382 (Pubitemid 29036497)
11. Trajman A., Steffen R. E., Menzies D., Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulmonary Medicine 2013 2013 11 2-s2.0-84876511204 10.1155/2013/601737 601737
12. Santin M., Muñoz L., Rigau D., Interferon- γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS ONE 2012 7 3 2-s2.0-84857749048 10.1371/journal.pone.0032482 e32482
13. Cattamanchi A., Smith R., Steingart K. R., Metcalfe J. Z., Date A., Coleman C., Marston B. J., Huang L., Hopewell P. C., Pai M., Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. Journal of Acquired Immune Deficiency Syndromes 2011 56 3 230 238 2-s2.0-79951811907 10.1097/QAI.0b013e31820b07ab
14. Denkinger C. M., Dheda K., Pai M., Guidelines on interferon- γ release assays for tuberculosis infection: concordance, discordance or confusion? Clinical Microbiology and Infection 2011 17 6 806 814 2-s2.0-79959291025 10.1111/j.1469-0691.2011.03555.x
15. Canada Communicable Disease Report, Recommendations on interferon gamma release assays for the diagnosis of latent tuberculosis infection-2010 update. Canada Communicable Disease, An Advisory Committee Statement (ACS) and Canadian Tuberculosis Committee (CTC) 2010 36 5
16. Centers for Disease Control and Prevention, Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. Morbidity and Mortality Weekly Report: Recommendations and Reports 2010 59 5 1 25
17. Erkens C. G. M., Kamphorst M., Abubakar I., Bothamley G. H., Chemtob D., Haas W., Migliori G. B., Rieder H. L., Zellweger J., Lange C., Tuberculosis contact investigation in low prevalence countries: a European consensus. European Respiratory Journal 2010 36 4 925 949 2-s2.0-77956599594 10.1183/09031936.00201609
18. Steffen R. E., Caetano R., Pinto M., Chaves D., Ferrari R., Bastos M., de Abreu S. T., Menzies D., Trajman A., Cost-effectiveness of quantiferon-TB gold-in-tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PLoS ONE 2013 8 4 2-s2.0-84875917971 10.1371/journal.pone.0059546 e59546
19. Ministério da Saúde (Brasil), Secretaria de Vigilância em Saúde, Programa Nacional de DST e Aids, Critérios de definição de casos de aids em adultos e crianças 2003 Brasília, Brazil Ministério da Saúde
20. Cellestis, QuantiFERON-TB Gold: Método in tubo, Teste de interferon-gama para sangue total, para medição de respostas aos péptidos antigénicos ESAT-6, CFP-10 & TB7. 7, Folleto informativo para diagnóstico in vitro 2009 Hannover, Germany Cellestis Limited, Australia e Cellestis GmbH
21. Ministério da Saúde (Brasil), Secretaria de Vigilância em Saúde, Programa Nacional de Controle da Tuberculose, Manual de Recomendações para o Controle da Tuberculose no Brasil 2011 Brasília, Brazil Ministério da Saúde
22. Luetkemeyer A. F., Charlebois E. D., Flores L. L., Bangsberg D. R., Deeks S. G., Martin J. N., Havlir D. V., Comparison of an interferon- γ release assay with tuberculin skin testing in HIV-infected individuals. The American Journal of Respiratory and Critical Care Medicine 2007 175 7 737 742 2-s2.0-34047231078 10.1164/rccm.200608-1088OC (Pubitemid 46536491)
23. Santin M., Casas S., Saumoy M., Andreu A., Moure R., Alcaide F., Ferrer E., Podzamczer D., Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon- γ release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagnostic Microbiology and Infectious Disease 2011 69 1 59 65 2-s2.0-78649930114 10.1016/j.diagmicrobio. 2010.09.005
24. Talati N. J., Seybold U., Humphrey B., Aina A., Tapia J., Weinfurter P., Albalak R., Blumberg H. M., Poor concordance between interferon- γ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infectious Diseases 2009 9, article 15 2-s2.0-61749083640 10.1186/1471-2334-9-15
25. Stephan C., Wolf T., Goetsch U., Bellinger O., Nisius G., Oremek G., Rakus Z., Gottschalk R., Stark S., Brodt H., Staszewski S., Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS 2008 22 18 2471 2479 2-s2.0-57349168026 10.1097/QAD.0b013e3283188415
26. Teixeira E. G., Menzies D., Comstock G. W., Cunha A. J. L. A., Kritski A. L., Soares L. C., Bethlem E., Zanetti G., Ruffino-Netto A., Belo M. T. C. T., Selig L., Branco M. M. C., Cherri D., Maia S., Marandino R., Luiz R. R., Chaisson R. E., Trajman A., Latent tuberculosis infection among undergraduate medical students in Rio de Janeiro State, Brazil. International Journal of Tuberculosis and Lung Disease 2005 9 8 841 847 2-s2.0-23744501150 (Pubitemid 41139640)
27. Siqueira K. Z., Mendonça S. A., Indicação da prova tuberculínica e infecção latente da tuberculose em HIV-positivos, Município de Blumenau, Estado de Santa Catarina, Brasil, 2004-2009. Epidemiologia e Serviços de Saúde 2012 21 4 635 644
28. Ramos J. M., Robledano C., Masiá M., Belda S., Padilla S., Rodríguez J. C., Gutierrez F., Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: a comparison of QuantiFERON-TB gold in tube, T-SPOT.TB and tuberculin skin test. BMC Infectious Diseases 2012 12, article 169 2-s2.0-84864325902 10.1186/1471-2334-12-169
29. Narasimhan P., Wood J., MacIntyre C. R., Mathai D., Risk factors for tuberculosis. Pulmonary Medicine 2013 2013 11 828939 10.1155/2013/828939
30. Clark S. A., Martin S. L., Pozniak A., Steel A., Ward B., Dunning J., Henderson D. C., Nelson M., Gazzard B., Kelleher P., Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clinical and Experimental Immunology 2007 150 2 238 244 2-s2.0-35348934353 10.1111/j.1365-2249.2007.03477.x (Pubitemid 47609557)
31. Aichelburg M. C., Rieger A., Breitenecker F., Pfistershammer K., Tittes J., Eltz S., Aichelburg A. C., Stingl G., Makristathis A., Kohrgruber N., Detection and prediction of active tuberculosis disease by a whole-blood interferon- γ release assay in HIV-l-infected individuals. Clinical Infectious Diseases 2009 48 7 954 962 2-s2.0-63649149534 10.1086/597351
32. Akolo C., Adetifa I., Shepperd S., Volmink J., Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2010 1 CD000171 2-s2.0-77950913100
33. World Health Organization, Use of Tuberculosis Interferon-Gamma Release Assays (IGRAs) in Low- and Middle-Income Countries: Policy Statement 2011 Geneva, Switzerland World Health Organization
34. Ministério da Saúde (Brasil), Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais, Boletim Epidemiológico-Aids e DST 2013 Ministério da Saúde Ano II-no. 1, até semana epidemiológica 26a